The objective of this model-based analysis was to estimate the potential cost-effectiveness of margetuximab compared to trastuzumab, each combined with chemotherapy, for patients with pretreated ERBB2-positive advanced breast cancer in developed and developing countries, like the US and China. Here, ERBB2 is linked to breast cancer.